NASDAQ:PSNL
Personalis Inc. Stock News
$1.30
-0.0100 (-0.763%)
At Close: May 31, 2024
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
09:05am, Wednesday, 22'nd May 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring da
Antares Bolsters Private Wealth Team with Three New Senior Appointments
09:00am, Wednesday, 22'nd May 2024
CHICAGO--(BUSINESS WIRE)--Antares Capital (“Antares”), a leading alternative asset manager with more than $69B in capital under management and administration, today announced three new senior hire
Q2 2024 Earnings Estimate for The Progressive Co. Issued By William Blair (NYSE:PGR)
01:06am, Monday, 20'th May 2024
The Progressive Co. (NYSE:PGR – Free Report) – Equities researchers at William Blair increased their Q2 2024 earnings estimates for Progressive in a research report issued to clients and i
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 17'th May 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant
Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript
11:53pm, Wednesday, 08'th May 2024
Personalis, Inc. (NASDAQ:PSNL ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Chris Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Ch
Personalis to Announce First Quarter 2024 Financial Results
04:01pm, Wednesday, 24'th Apr 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday,
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
04:01pm, Thursday, 28'th Mar 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual He
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
09:00am, Thursday, 28'th Mar 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for th
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company's NeXT Personal test,
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:43pm, Tuesday, 19'th Mar 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
09:20pm, Wednesday, 28'th Feb 2024
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
04:01pm, Wednesday, 14'th Feb 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial result
Personalis to Participate at Upcoming Investor Conferences
04:01pm, Wednesday, 31'st Jan 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor confere
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
09:00am, Tuesday, 30'th Jan 2024
FREMONT, Calif. & SAN DIEGO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveile
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 17'th Jan 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant